The Chao Family Comprehensive Cancer Center (CFCCC) Anti-Cancer Challenge (ACC) is accepting applications for cancer-related pilot projects.

The overall objectives of the CFCCC ACC Pilot Project Program are to: (1) increase the number of extramural peer-reviewed grant awards, particularly collaborative and multi-PI grants; (2) support the development of investigator-initiated early phase clinical trial protocols by clinical investigators, particularly interventional trials; (3) advance novel diagnostic or screening technologies, therapeutic molecules or devices, and bio-behavioral interventions from bench to bedside; and (4) advance research on cancer control, cancer population science, and pediatric cancers.

**KEY DATES**

- Letters of Intent Due: January 26, 2023 (5:00 pm PST)
- Applications Due: March 6, 2023 (5:00 pm PST)
- Scientific Merit Review: April 2023
- Notifications of Award: May 2023
- Earliest Funding Start Date: June 1, 2023

**ELIGIBILITY**

- Principal Investigators (PIs) must be UCI researchers (e.g., faculty or project scientists), CHOC Hyundai Cancer Institute-affiliated physicians, or collaborators at the Long Beach VA Medical Center.
- The PI of the award must be a CFCCC Member or Associate Member at the time of award.
- Projects must be capable of significant impact within 1-2 years.

**AWARDS**

Applicants may apply to one of these five distinct opportunities. Investigators may only submit one application as a PI.

<table>
<thead>
<tr>
<th>EARLY-STAGE INVESTIGATOR AWARD</th>
<th>STANDARD AWARD</th>
<th>MULTI-PI (TEAM SCIENCE) AWARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>$20,000</td>
<td>$40,000</td>
<td>$60,000</td>
</tr>
</tbody>
</table>

This opportunity provides support for early-stage investigators.
The PI must meet the basic eligibility requirements and be an early-stage investigator (ESI) as defined by NIH:
- Must have completed their terminal research degree or end of post-graduate clinical training, whichever is later, within the last 10 years
- Must not have previously competed successfully as PI for a substantial NIH independent research award

<table>
<thead>
<tr>
<th>UNDERREPRESENTED INVESTIGATOR AWARD</th>
<th>RE-ENTRY AFTER FAMILY CARE AWARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>$40,000</td>
<td>$40,000</td>
</tr>
</tbody>
</table>

This opportunity provides support for:
- Investigators from historically disenfranchised racial and ethnic groups that are under-represented in health sciences and cancer research,
- Individuals with physical or mental disabilities that substantially limits one or more major life activities, or
- Those with a personal or professional background of economic disadvantage

Refer to the [NIH operational definitions of under-represented groups](https://www.nih.gov/niaid/about-niaid/liaisons-diversity-advanced-research). Research can be in any area relevant to the RFP.

This opportunity provides support for investigators whose research has been interrupted for at least 6 months by significant but temporary family care responsibilities (e.g., childbirth; childbearing complications; child-rearing; caring for an ill, disabled, or elderly family member).

Funds are meant to provide support for ongoing research and assist with addressing gaps in research productivity (e.g., obtaining preliminary data for grant submission).

Applicants must demonstrate a compelling need that is related to research activity interruption due to caregiving responsibilities and are expected to describe the caregiving burden and impact of this caregiving on capacity to conduct research and/or financially support their research program.
RESEARCH SCOPE
Applicants may request one year (Track 1) or two years (Track 2) of support.

<table>
<thead>
<tr>
<th>TRACK 1</th>
<th>TRACK 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Limited to 1 year</strong></td>
<td><strong>Limited to 2 years</strong></td>
</tr>
<tr>
<td>• Basic, translational, or population-based cancer science projects</td>
<td>• Early Phase Clinical Research, with the goal of launching an interventional investigator-initiated clinical trial at UCI Health within 1 year</td>
</tr>
<tr>
<td>• Expected to generate pilot data necessary for obtaining peer-reviewed extramural grants (e.g., NIH R01) or enable additional data collection to respond to prior critiques for resubmission applications (NIH A1 applications)</td>
<td>• Not necessarily expected to lead to extramural peer-reviewed funding, but pharmaceutical industry co-sponsorship is encouraged</td>
</tr>
<tr>
<td></td>
<td>• Projects must be managed by the Stern Center for Cancer Clinical Trials &amp; Research and must meet the following criteria:</td>
</tr>
<tr>
<td></td>
<td>o Developed in collaboration with a CFCCC Disease-Oriented Team or a multidisciplinary tumor board</td>
</tr>
<tr>
<td></td>
<td>o Include a DOT-approved clinical protocol</td>
</tr>
<tr>
<td></td>
<td>o Capable of obtaining full regulatory approval (e.g., IRB) within 6 months of award</td>
</tr>
</tbody>
</table>

PRIORITY AREAS

- **Cancer Health Disparities in Orange County, CA**
  This includes research addressing:
  o Cancers with unusually high rates of incidence, prevalence, or mortality in Orange County, such as melanoma, breast, and lung cancer
  o Cancers disproportionately affecting racial or ethnic groups in Orange County, such as liver and gastric cancer in Hispanics and Asians, cervical, gall bladder, and young onset colorectal cancer in Hispanics
  o Projects that address unique aspects of a specific cancer burden in Orange County (e.g., etiology of lung adenocarcinoma in Asian female never-smokers or of Ph-like B-lymphoblastic leukemia in Hispanics; basis for low HPV vaccination rates in different racial/ethnic groups; melanoma detection/prognosis in Hispanics)
  o Learn more about cancer health disparities, the CFCCC catchment area, and catchment area demographics and cancer incidence and mortality

- **Cancer Control and Population Science**
  Particularly those projects that involve collaborations with Cancer Control Program researchers

- **Pediatric and Adolescent/Young Adult Populations**
  Basic, translational, or investigator-initiated clinical research on cancers impacting these populations

- **Development of Investigator-Initiated Trials (IIT)** in the detection, prevention, or treatment of cancer:
  o Priority will be given to studies that show high potential to progress to next phase trials, to expand to multiple sites (e.g., through the UC Consortium), or to be elevated to a national level (National Clinical Trials Network (NCTN))
  o Collaborations involving Disease-Oriented Teams or multidisciplinary tumor boards seeking to advance a novel diagnostic or screening technology, therapeutic molecule or device, or bio-behavioral intervention to a clinical trial

SPECIAL INTEREST AREA: COMMUNITY ENGAGEMENT
Of special interest are projects where engagement of communities informs and results in high-impact science. This includes projects with community partners and/or projects that engage community stakeholders in research development, methods, analyses, dissemination of results, and/or implementation of evidence-based interventions.

Webinar to learn more about engaging communities in research:

**Date and Time:** Monday, January 30, 2023 (12:00 pm-1:00 pm)

**To Join Zoom Meeting:** [Click here](#)

**To call in:**
- +1 669 444 9171
- Meeting ID: 916 4828 8242
- Passcode: 533552

The webinar will be recorded and accessible from the CFCCC website for those unable to attend.
APPLICATION GUIDELINES

A. Contact for inquiries: cfcccpilots@hs.uci.edu

B. Application Components
   a. Letter of Intent (Due January 26, 2023 by 5:00 pm PST)
      • Letters of intent are optional but are highly encouraged. They are non-binding and will be used for planning the application review.
      • Submit your LOI using this online form: https://ci-redcap.hs.uci.edu/surveys/?s=KFHPMXNT798NC38R
   b. Full Application (Due March 6, 2023 by 5:00 pm PST)
      • A complete application will include these components.
        i. Project Detail Cover Sheet (online form)
        ii. Research Proposal (downloadable template)
           ▪ Scientific Abstract
           ▪ Community Relevance Statement
           ▪ Research Strategy (limited to 3 pages)
           ▪ Leadership Plan (for multi-PI applications)
           ▪ Bibliography/References Cited
           ▪ Detailed Budget & Budget Justification
        iii. NIH-formatted Biosketches for Key Personnel
      • Download the proposal template and submit your complete application through this online form: https://ci-redcap.hs.uci.edu/surveys/?s=JMED34HF8RDXDE44

C. Budgets
   • Unallowable costs: PI salaries (salaries for project staff are allowable), large equipment (e.g., >$5K), travel, and indirect costs.
   • Funding from the Anti-Cancer Challenge are gift funds, no indirect costs will be awarded.
   • Funds must be fully spent within the award period.
   • Co-funding is allowable and may be described in the application. However, co-funding is not required.

D. Review Criteria

<table>
<thead>
<tr>
<th>EARLY-STAGE INVESTIGATOR AWARD</th>
<th>STANDARD AWARD</th>
<th>MULTI-PI (TEAM SCIENCE) AWARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>$20,000</td>
<td>$40,000</td>
<td>$60,000</td>
</tr>
</tbody>
</table>

Standard Award review criteria apply.

ESI applications will be reviewed in a separate pool. In addition, peer reviewers are instructed to focus more on the proposed approach than on track record, and to expect less preliminary data than would be provided by established investigators.

Applications will be peer reviewed in accordance with NIH’s scoring system with explicit emphasis placed on the near-term impact (i.e., within 1-2 years). Applicants will receive a copy of the review comments in an anonymous format.

Projects that address one or more of the priority areas will be scored more favorably.

Projects that extend basic science to a clinical or translational capacity, leverage CFCCC Shared Resources, collaborate with DOTS, or involve significant new collaborations will be ranked more favorably.

Inter/intra-programmatic collaboration between Cancer Center members are strongly encouraged.

Standard Award review criteria apply.

In addition, peer reviewers are instructed to evaluate whether the scientific goals of the project justify a multi-PI (team science) approach. As with NIH P01 applications, it is expected that the multiple components of the applications are stronger together than if submitted separately.

<table>
<thead>
<tr>
<th>UNDER-REPRESENTED INVESTIGATOR AWARD</th>
<th>RE-ENTRY AFTER FAMILY CARE AWARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>$40,000</td>
<td>$40,000</td>
</tr>
</tbody>
</table>

Standard Award review criteria apply.

Standard Award review criteria apply.
E. Regulatory Approvals

Prior to the release of funding:

- All projects involving human subjects must have IRB approval. If sufficient progress in obtaining regulatory approvals has not been made within 6 months after award date, the CFCCC may withdraw funding.
- All projects involving animal subjects must have the appropriate IACUC approvals.
- All projects involving biohazards and subject to review by the IBC must have those approvals in place.

F. Reporting

- As a requirement of federal and philanthropic funding, Cancer Center Administration will track the outcomes of each award through annual progress and impact reports to determine the return on investment. Portions of a report or the report as a whole may be shared with the community or donors upon request.
  - Progress Reports: Due 12 months (Track 1) or 24 months (Track 2) from the start date of the award.
  - Impact Reports: Due annually for a period of 5 years after the project end date.
- Awardees may be asked or have the option to present a 15-20 minute “chalk talk” to a peer-colleague committee at the CFCCC Annual Scientific Retreat held in September of each year. Chalk talks are intended to help grantees prepare for extramural research grant submissions.

G. Donor Engagement

- Awardees will be asked to present at Anti-Cancer Challenge-related events and participate in video projects to help share the importance of supporting cancer-related pilot projects and the impact of ACC within the community.